Abstract: Medical devices, plug-ins, systems, and methods for CPR quality feedback are disclosed. The medical devices can calculate peripheral circulation relevant parameters based on measured signals containing at least partial hemodynamic characteristics. Amplitude and area characteristics included in the peripheral circulation relevant parameters can further be determined for providing feedback and control relating to CPR quality during the compression process. Also, compression interruption during CPR can be evaluated based on a pulse waveform generated from the measured signals.
Type:
Grant
Filed:
March 21, 2018
Date of Patent:
November 5, 2019
Assignees:
PEKING UNION MEDICAL COLLEGE HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES, SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
Inventors:
Jun Xu, Xuezhong Yu, Fei Han, Liangliang Zheng, Cheng Wang, Xiaocui Zhang, Chen Li, Jingming Yang, Xingliang Jin
Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis, or preventing and/or treating a liver injury, or improving a liver function, or preventing and/or treating a liver disease associated with liver fibrosis, for modulating (e.g. reducing) the content of collagen (e.g. type I collagen) in liver tissue, for modulating (e.g. inhibiting) the activity of COL1A1 promoter in a cell, and for modulating (e.g. inhibiting) expression level of a gene associated with liver fibrosis in a cell.
Type:
Application
Filed:
November 24, 2016
Publication date:
September 12, 2019
Applicants:
Hebei Medfaith Pharmaceutical Technology Co., Ltd., Institute of Medicinal Biotechnology Chinese Academy of Medical Sciences
Abstract: The present invention relates to a method for diagnosing lung cancers such as non-small lung cancer in a subject by using isocitrate dehydrogenase 1 as a diagnostic biomarker. The present invention also relates to a method for predicting the prognosis of the lung cancers such as non-small lung cancer in a subject by using isocitrate dehydrogenase 1 as a prognostic biomarker. The present invention further relates to a method of suppressing proliferation of lung tumor cells in a subject, decreasing growth of lung tumor cells in a subject, or improving survival of a subject with lung cancer by using isocitrate dehydrogenase 1 as a therapeutic target.
Type:
Grant
Filed:
September 28, 2017
Date of Patent:
July 23, 2019
Assignee:
Cancer Hospital, Chinese Academy of Medical Sciences
Inventors:
Jie He, Fengwei Tan, Zhaoli Chen, Nan Sun
Abstract: A group of polypeptides and a complex formed by the polypeptides and human serum albumin, a method for improving the solubility of the group of polypeptides in a salt solution by combining the polypeptides with human serum albumin, a method for preparing the complex formed by the group of polypeptides and human serum albumin, and an application of the group of polypeptides and the complex formed by the polypeptides and human serum albumin in the preparation of drugs for suppressing tumor metastasis and treating leukemia are described.
Type:
Grant
Filed:
July 1, 2015
Date of Patent:
April 16, 2019
Assignees:
National Center for Nanoscience and Technology, China, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences
Abstract: Provided are a new aromatic cyanogen compound and a preparation method thereof. The present invention also relates to the use of such compound in antiviral drugs, in particular the use thereof in anti-HCV drugs.
Type:
Grant
Filed:
August 17, 2016
Date of Patent:
April 9, 2019
Assignee:
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
Abstract: The present invention provides N6-substituted adenosine derivatives and N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising the said compounds above, and uses of these compounds in manufacturing medicaments and health-care products for treating insomnia, convulsion, epilepsy, and Parkinson's diseases, and preventing and treating dementia.
Type:
Grant
Filed:
December 10, 2009
Date of Patent:
January 8, 2019
Assignee:
INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
Inventors:
Jiangong Shi, Jianjun Zhang, Zhenggang Yue, Min Li, Chenggen Zhu, Ying Zhang, Jiachen Zi, Yafang Wang, Xiaona Fan, Ruiming Xu, Sheng Lin, Yan Li, Yongchun Yang, Li Sheng
Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis, or preventing and/or treating a liver injury, or improving a liver function, or preventing and/or treating a liver disease associated with liver fibrosis, for modulating (e.g. reducing) the content of collagen (e.g. type I collagen) in liver tissue, for modulating (e.g. inhibiting) the activity of COL1A1 promoter in a cell, and for modulating (e.g. inhibiting) expression level of a gene associated with liver fibrosis in a cell.
Type:
Application
Filed:
November 24, 2016
Publication date:
November 22, 2018
Applicants:
Hebei Medfaith Pharmaceutical Technology Co., Ltd., Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
Abstract: The present invention provides a method for treating leukemia utilizing somatic cell reprogramming. The method includes a step of introduction of somatic cell reprogramming inducing factors Oct-4, Sox-2, Klf4 and c-Myc (OSKM for short) into leukemic cells or a step of utilizing small reprogramming molecules in in-vitro culture. It promotes leukemic cells to initiate process of somatic cell reprogramming in order to induce apoptosis and finally purpose of eliminating leukemic cells in-vivo or in-vitro is achieved. It provides new ideas and methods for clinical treatment of leukemia in the future.
Type:
Application
Filed:
July 22, 2016
Publication date:
August 16, 2018
Applicant:
Institute of Hematology and Blood Disease Hospital Chinese Academy of Medical Sciences and Peking
Abstract: The invention discloses a use of paracetamol and a pharmaceutical preparation containing the same in preparation of anti-HPV drugs. The novel anti-HPV pharmaceutical preparation of the invention has a significant anti-HPV effect and low toxicity, and can be used for preventing and treating clinical symptoms caused by HPV infection, especially common warts, plane warts, plantar wart, vulvar cancer, penile neoplasms, anal carcinoma, prostate cancer, bladder cancer, cervical cancer, rectal cancer, oral cancer, tonsil cancer and the like.
Type:
Grant
Filed:
July 14, 2014
Date of Patent:
August 14, 2018
Assignee:
INSTITUTE OF BIOMEDICAL ENGINEERING, CHINESE ACADEMY OF MEDICAL SCIENCE
Inventors:
Tianjun Liu, Shuai Meng, Lihui Zhao, Ge Hong
Abstract: The present invention relates to a method for diagnosing the lung cancers such as non small lung cancer in a subject by using isocitrate dehydrogenase 1 as a diagnostic biomarker. The present invention also relates to a method for predicting the prognosis of the lung cancers such as non small lung cancer in a subject by using isocitrate dehydrogenase 1 as a prognostic biomarker. The present invention further relates to a method to suppress proliferation of lung tumor cells in a subject, decrease growth of lung tumor cells in a subject, or improve survival of a subject with lung cancer by using isocitrate dehydrogenase 1 as a therapeutic target.
Type:
Grant
Filed:
September 13, 2012
Date of Patent:
October 24, 2017
Assignee:
Cancer Hospital, Chinese Academy of Medical Sciences
Inventors:
Jie He, Fengwei Tan, Zhaoli Chen, Nan Sun
Abstract: The present invention provides a humanized monoclonal antibody against extracellular domain of human death receptor 5, comprising a light chain variable region, whose amino acid sequence has at least 90% identity with the amino acid sequence shown as SEQ ID NO: 1, a heavy chain variable region, whose amino acid sequence has at least 90% identity with the amino acid sequence shown as SEQ ID NO: 2, and constant region derived from human antibody. The present invention also provides nucleotide sequence encoding said humanized monoclonal antibody, a recombinant eukaryotic expression vector, a process for preparing the humanized monoclonal antibody, and the composition and use therefore.
Type:
Grant
Filed:
October 26, 2012
Date of Patent:
August 8, 2017
Assignee:
Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences
Abstract: The present invention relates to the pharmaceutical field, in particular to a phenanthridine derivative as shown in general formula (1) a pharmaceutical composition comprising the derivative, its preparation method, and its uses in manufacture of a medicament for the prevention or treatment of a disease related to the activity of Wnt signaling pathway, hepatitis C and hepatitis B.
Type:
Grant
Filed:
February 28, 2014
Date of Patent:
June 20, 2017
Assignees:
Kunming Institute of Botany, The Chinese Academy of Sciences, Shanghai Institutes for Biological Sciences, CAS, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
Inventors:
Xiaojiang Hao, Duozhi Chen, Lin Li, Zonggen Peng, Jiandong Jiang, Yingtong Di, Junlin Yin, Sheng Wang, Jieyun Cai
Abstract: The present invention relates to use of a microRNA or an inhibitor thereof, and specifically, the present invention relates to use of a microRNA or an inhibitor thereof in preparing a medicament for regulating lipid metabolism or preparing a medicament for preventing or treating a disease related to lipid metabolism. The microRNA is one or more of the following: miRNA-96, miRNA-185, and miRNA-223. The present invention also relates to use of the microRNA or the inhibitor thereof in regulating the expression level of a protein related to lipid metabolism. The present invention also relates to a composition comprising the microRNA or the inhibitor thereof. The microRNA or the inhibitor thereof in the present invention can be used as a pharmaceutical component, and can be applied in preventing or treating a disease caused by lipid metabolism disorders such as hyperlipidemia, atherosclerosis, coronary heart disease or other diseases.
Type:
Grant
Filed:
January 26, 2014
Date of Patent:
April 11, 2017
Assignee:
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
Inventors:
Bin Hong, Li Wang, Xiaojian Jia, Huajun Jiang, Yu Du, Fan Yang, Shuyi Si
Abstract: The present invention discloses an Albizzia chinensis extract used in the preparation of a drug for the treatment of gastric ulcers. Specifically, it discloses an Albizzia chinensis (Osbeck) Merr extract and its preparation method including the stems bark of Albizzia chinensis was successively grounded, extracted, concentrated and purificated, as well as a pharmaceutical composition comprising the Albizzia chinensis extract. Through pharmacological test, it has been demonstrated that, the Albizzia chinensis extract showed strong inhibition activity against proton pumps, and it can be used for the treatment of gastric ulcers, chronic gastritis and other acid-related diseases, and its anti-ulcer effect is significant, quick, safe and reliable.
Type:
Grant
Filed:
October 24, 2012
Date of Patent:
July 19, 2016
Assignee:
Institute of Materia Medica, Chinese Academy of Medical Sciences
Abstract: Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the present invention having the pharmacological activities such as anti-virus, anti-virus-infection, nerve protection, anti-metabolic-diseases and the like. Also provided is a chemical total synthesis preparation method of the natural products cajanine, cajanine A and cajanine C. The present invention lays a foundation for the in-depth study and development of the compounds as clinical drugs in the future.
Type:
Grant
Filed:
December 18, 2012
Date of Patent:
June 7, 2016
Assignee:
INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCES
Abstract: The present invention relates to use of a microRNA or an inhibitor thereof, and specifically, the present invention relates to use of a microRNA or an inhibitor thereof in preparing a medicament for regulating lipid metabolism or preparing a medicament for preventing or treating a disease related to lipid metabolism. The microRNA is one or more of the following: miRNA-96, miRNA-185, and miRNA-223. The present invention also relates to use of the microRNA or the inhibitor thereof in regulating the expression level of a protein related to lipid metabolism. The present invention also relates to a composition comprising the microRNA or the inhibitor thereof. The microRNA or the inhibitor thereof in the present invention can be used as a pharmaceutical component, and can be applied in preventing or treating a disease caused by lipid metabolism disorders such as hyperlipidemia, atherosclerosis, coronary heart disease or other diseases.
Type:
Application
Filed:
January 26, 2014
Publication date:
March 31, 2016
Applicant:
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences
Inventors:
Bin HONG, Li WANG, Xiaojian JIA, Huajun JIANG, Yu DU, Fan YANG, Shuyi SI
Abstract: Disclosed are derivatives of protoberberine biological alkaloids or physiologically acceptable salts thereof produced by means of a derivative reaction of a source material of biological alkaline quaternary ammonium salts of protoberberine alkaloids, a preparation method for same and pharmaceutical uses thereof. The derivatives of protoberberine biological alkaloids or the physiologically acceptable salts thereof show activity inhibiting ulcerative colitis and can be used in the preparation of drugs for same.
Type:
Grant
Filed:
October 24, 2012
Date of Patent:
February 23, 2016
Assignee:
Institute of Materia Medica, Chinese Academy of Medical Sciences
Abstract: Disclosed is a biomimetic adhesive belonging to prevention and treatment of plant pest. The components and ratio of raw materials thereof are as follows: 25-50% of soft acrylic monomer, 1-5% of acrylic monomer, 0.1-0.3% of nonionic emulsifier, 0.1-0.8% of anionic emulsifier, 0.2-0.6% of catalyst, 0.1-0.3% of antiseptic, 0.02-0.05% of defoamer, and deionized water as remainder. Fluorescent substances or insect pheromones can also be added to said biomimetic adhesive. The biomimetic adhesive of the present invention has good effect of insect sticking without environmental impact, has long time effect, is safe, non-toxic and non-polluting, and can be sprayed directly onto the surface of plant branch and leaves using an ordinary sprayer due to its low viscosity at room temperature. It also has no adverse effects on photosynthesis and normal growth of plants. The preparation method of the biomimetic adhesive is also disclosed.
Type:
Grant
Filed:
November 29, 2010
Date of Patent:
January 5, 2016
Assignees:
Institute of Medicinal Plant Development The Chinese Academy of Medical Sciences, Foshan Sanshui Xianghai Adhesive Co., Ltd.
Abstract: A novel glycosyl hydrolase with activities of beta-xylosidase and beta-glucosidase is provided. Said glycosyl hydrolase can convert 7-xylosyltaxane compounds to 7-hydroxyltaxane compounds.
Type:
Grant
Filed:
April 12, 2011
Date of Patent:
December 8, 2015
Assignee:
Institute of Materia Medica, Chinese Academy of Medical Sciences